DE602006009773D1 - Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen - Google Patents

Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen

Info

Publication number
DE602006009773D1
DE602006009773D1 DE602006009773T DE602006009773T DE602006009773D1 DE 602006009773 D1 DE602006009773 D1 DE 602006009773D1 DE 602006009773 T DE602006009773 T DE 602006009773T DE 602006009773 T DE602006009773 T DE 602006009773T DE 602006009773 D1 DE602006009773 D1 DE 602006009773D1
Authority
DE
Germany
Prior art keywords
glucagon receptor
preparation
receptor antagonists
compounds
therapeutic applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006009773T
Other languages
English (en)
Inventor
Mark Donald Chappell
Scott Eugene Conner
Allie Edward Tripp
Guoxin Shanghai Che Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006009773(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602006009773D1 publication Critical patent/DE602006009773D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602006009773T 2005-02-11 2006-02-09 Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen Active DE602006009773D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65249205P 2005-02-11 2005-02-11
PCT/US2006/004461 WO2006086488A2 (en) 2005-02-11 2006-02-09 Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
DE602006009773D1 true DE602006009773D1 (de) 2009-11-26

Family

ID=36694345

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006009773T Active DE602006009773D1 (de) 2005-02-11 2006-02-09 Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen

Country Status (25)

Country Link
US (1) US8084489B2 (de)
EP (1) EP1856090B1 (de)
JP (1) JP4988604B2 (de)
KR (1) KR20070104409A (de)
CN (1) CN101115735B (de)
AT (1) ATE445609T1 (de)
AU (1) AU2006213894B2 (de)
BR (1) BRPI0607015A2 (de)
CA (1) CA2597073C (de)
CR (1) CR9304A (de)
CY (1) CY1109624T1 (de)
DE (1) DE602006009773D1 (de)
DK (1) DK1856090T3 (de)
EA (1) EA200701705A1 (de)
ES (1) ES2332470T3 (de)
IL (1) IL184932A0 (de)
MA (1) MA29432B1 (de)
MX (1) MX2007009661A (de)
NO (1) NO20074567L (de)
PL (1) PL1856090T3 (de)
PT (1) PT1856090E (de)
SI (1) SI1856090T1 (de)
TN (1) TNSN07313A1 (de)
WO (1) WO2006086488A2 (de)
ZA (1) ZA200706354B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014426A (es) * 2004-06-14 2007-03-01 Lilly Co Eli Antagonistas del receptor de glucagon, preparacion y usos therapeuticos.
WO2008098244A1 (en) 2007-02-09 2008-08-14 Metabasis Therapeutics, Inc. Novel antagonists of the glucagon receptor
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2966273C (en) 2008-08-13 2019-08-27 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
CN104744370A (zh) 2011-02-08 2015-07-01 辉瑞大药厂 胰高血糖素受体调节剂
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
BR112014000288A2 (pt) 2011-07-22 2017-01-10 Pfizer moduladores do receptor de glucagon de quinolinila
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
EP3065736B1 (de) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon-rezeptor-antagonist-verbindungen, zusammensetzungen daraus und verfahren zur verwendung
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CA2998862A1 (en) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
CA2914601A1 (en) * 2015-12-11 2017-06-11 Wake Forest University Health Sciences Angiotensin-(1-7) analogs and methods relating thereto
EP3506940A1 (de) 2016-08-30 2019-07-10 Regeneron Pharmaceuticals, Inc. Verfahren zur behandlung schwerer insulinresistenz durch interferenz mit glucagonrezeptorsignalisierung
EP3529278A1 (de) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Verfahren zur senkung des blutzuckerspiegels
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
US20210121422A1 (en) 2018-02-13 2021-04-29 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
EP4285723A3 (de) 2019-12-20 2024-03-27 Bayer Aktiengesellschaft Substituierte thiophencarboxamide thiophencarbonsäuren und deren derivate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365622A1 (en) * 2001-12-03 2003-06-17 Novo Nordisk A/S Novel glucagon antagonists
EP1519723A1 (de) 2002-06-27 2005-04-06 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
WO2005118542A1 (en) * 2004-05-28 2005-12-15 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
MXPA06014426A (es) 2004-06-14 2007-03-01 Lilly Co Eli Antagonistas del receptor de glucagon, preparacion y usos therapeuticos.

Also Published As

Publication number Publication date
WO2006086488A2 (en) 2006-08-17
US8084489B2 (en) 2011-12-27
AU2006213894B2 (en) 2011-12-08
NO20074567L (no) 2007-11-08
JP4988604B2 (ja) 2012-08-01
CA2597073C (en) 2014-11-25
DK1856090T3 (da) 2009-11-30
IL184932A0 (en) 2007-12-03
ES2332470T3 (es) 2010-02-05
EA200701705A1 (ru) 2008-02-28
SI1856090T1 (sl) 2010-02-26
MX2007009661A (es) 2007-09-25
CY1109624T1 (el) 2014-08-13
KR20070104409A (ko) 2007-10-25
TNSN07313A1 (en) 2008-12-31
CR9304A (es) 2008-03-31
WO2006086488A3 (en) 2006-12-14
EP1856090A2 (de) 2007-11-21
BRPI0607015A2 (pt) 2009-12-01
ATE445609T1 (de) 2009-10-15
US20100137417A1 (en) 2010-06-03
MA29432B1 (fr) 2008-05-02
AU2006213894A1 (en) 2006-08-17
EP1856090B1 (de) 2009-10-14
PL1856090T3 (pl) 2010-02-26
ZA200706354B (en) 2008-11-26
CN101115735B (zh) 2013-01-09
CN101115735A (zh) 2008-01-30
PT1856090E (pt) 2009-11-18
CA2597073A1 (en) 2006-08-17
JP2008530102A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
DK1758853T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
DK1861360T3 (da) Pyrrolidin-derivater som histamin-H3-receptorantagonister
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN